HANNAH ALISON L. 4

What Happened

• Hannah Alison, Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals (RIGL), was granted 24,400 restricted stock units (RSUs) on July 8, 2026. The reported acquisition price is $0.00 (award), so no cash changed hands at grant.
• The RSUs will convert into shares upon vesting; the award vests annually over four years beginning July 8, 2027.

Key Details

• Transaction type/date: Award (code A) on 2026-07-08; reported on Form 4 filed 2026-07-10 (timely within standard Section 16 reporting window).
• Price/amount: 24,400 RSUs @ $0.00 (total $0 at grant reporting).
• Vesting: Annual vesting over 4 years from July 8, 2026; first vesting on July 8, 2027 (see footnote).
• Adjustment: Filing notes a prior cancellation of 5,750 RSUs for no consideration; amount was adjusted accordingly and the cancellation is reported as exempt from Section 16 under Rule 16b-6(d) and Rule 16a-4(d).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context

• RSUs are a form of equity compensation that convert to shares when they vest; an RSU grant is different from an open-market purchase or sale and does not by itself signal immediate buying or selling by the insider.
• Because vesting is spread over multiple years, the economic exposure to the company for the insider depends on future vesting and any subsequent sales.